The scientific research area of Prof. Caroline Kistorp lies in the complications of endocrine disorders, with a focus on heart failure (HF) and Cardiovascular disease (CVD) in patients with type 2 diabetes. Her work has demonstrated a high prevalence of type 2 diabetes and subsequent poor prognosis among patients with concomitant heart failure, and – in original data – has shown a key role of adipocyte dysfunction.
Prof. Kistorp have initiated various RCTs investigating the mechanism behind the markedly increased risk of HF and CVD deaths in type 2 diabetes, exploring new treatment strategies. In the multicentre LIVE RCT on GLP-1 RA treatment in heart failure, the clinical relevance of NT-proBNP reduction was demonstrated. In the MIRAD trial, increased activation of the mineralocorticoid receptor as a common mechanism between type 2 diabetes and CVD has been investigated, and with original data she demonstrated markedly reduced adipocyte fibrosis with an MR antagonist in type 2 diabetes patients. In the SIMPLE and EMPIRE RCTs, the mechanisms behind SGLT-2 inhibitors are investigated in patients with type 2 diabetes and heart failure respectively.